Cost-effectiveness analysis of using onasemnogene abeparvocec (AVXS-101) in spinal muscular atrophy type 1 patients

Background: Spinal muscular atrophy type 1 (SMA1) is a devastating genetic disease for which gene-replacement therapy may bring substantial survival and quality of life benefits. Objective: This study investigated the cost-effectiveness of onasemnogene abeparvovec (AVXS-101) gene-replacement therapy...

Full description

Saved in:
Bibliographic Details
Main Authors: Daniel C. Malone (Author), Rebecca Dean (Author), Ramesh Arjunji (Author), Ivar Jensen (Author), Phil Cyr (Author), Beckley Miller (Author), Benit Maru (Author), Douglas M. Sproule (Author), Douglas E. Feltner (Author), Omar Dabbous (Author)
Format: Book
Published: Taylor & Francis Group, 2019-01-01T00:00:00Z.
Subjects:
Online Access:Connect to this object online.
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

Connect to this object online.

3rd Floor Main Library

Holdings details from 3rd Floor Main Library
Call Number: A1234.567
Copy 1 Available